US5171251003 - Common Stock
LARIMAR THERAPEUTICS INC
NASDAQ:LRMR (5/3/2024, 7:04:08 PM)
After market: 7.765 0 (0%)7.765
+0.15 (+2.04%)
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 26 full-time employees. The company went IPO on 2014-06-19. The Company’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality. The company also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.
LARIMAR THERAPEUTICS INC
Three Bala Plaza East. Suite 506
Bala Cynwyd PENNSYLVANIA 19004
P: 18445119056
CEO: Carole Ben-Maimon
Employees: 26
Website: https://larimartx.com/
LRMR stock results show that Larimar Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Larimar Therapeutics (NASDAQ:LRMR) just reported results for the fourth quarter...
Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue...
Study will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin...
Here you can normally see the latest stock twits on LRMR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: